Varambally Lab Mission
Soory Varambally’s team focuses on understanding the molecular basis of cancer using integrative genomic, epigenetic, proteomic, cancer biology approach and therapeutic targeting.
The Varambally Lab’s translational cancer research involves transferring the basic research discoveries to develop disease detection markers of developing therapy for the identified targets. Our group worked extensively in the area of solid tumor genomics, biomarker discovery, biology, and therapeutic targeting. Our integrative cancer research helps better understand the molecular alterations during the initiation and progression of multiple human malignancies. In order to enhance the speed of the cancer research/target discovery and make the cancer research a global team effort, we built a discovery platform called UALCAN (http://ualcan.path.uab.edu) for cancer genomic and proteomic data analysis. This cancer research tool has since been extensively used.
Some of the candidate biomarkers and therapeutic targets that our research identified include Histone Methyltransferase EZH2, AMACR, TPD52, MTA1, ERG gene fusion, SPINK1, CtBP1, RAF kinase gene fusions, GOLM1, PAICS, P4HA1, GLYATL1 and JAGGED1 in prostate cancer, GATA3, AGTR1, EZH2, CCN6 (WISP3) in breast cancer, MTHFD1L, PAICS and PAK4 in bladder cancer, TRIP13, PAICS, MTHFD1L and P4HA1 in colon cancers, PAICS, PPAT and P4HA1 in lung cancers among others.